Company news
Tyra Biosciences, Inc. (NASDAQ:TYRA) news
Tyra Biosciences, Inc. news releases on 6ix. Latest, Sep 14, 2026: Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded…
Press releases & updates
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
September 14, 2026
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
September 9, 2026
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
September 8, 2026
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
September 4, 2026
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
August 4, 2026
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
May 21, 2026
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
May 13, 2026
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
April 17, 2026
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
March 2, 2026
Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium
February 23, 2026
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer
November 30, 2025
Tyra Biosciences Announces Participation at Upcoming Investor Events
November 11, 2025
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
November 4, 2025
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
August 20, 2025
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
August 13, 2025
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
July 20, 2025
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
July 7, 2025
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
June 29, 2025
Tyra Biosciences to Participate at Upcoming Investor Conferences
May 11, 2025
Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights
May 7, 2025
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
March 26, 2025
Tyra Biosciences to Present at Upcoming Investor Conferences
February 10, 2025
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
January 28, 2025
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
January 21, 2025
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
January 9, 2025
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
November 6, 2024
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
October 27, 2024
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
October 23, 2024
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
October 22, 2024
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
October 10, 2024
Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
September 9, 2024
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
August 6, 2024
Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
July 1, 2024
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
May 8, 2024
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
May 6, 2024
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
March 18, 2024
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
February 6, 2024
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
February 1, 2024
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
January 31, 2024
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
December 21, 2023
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
November 7, 2023
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
November 6, 2023
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
September 20, 2023
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
September 11, 2023
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
August 9, 2023
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
July 31, 2023
Tyra Biosciences to Participate in Upcoming Investor Conferences
May 24, 2023
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
May 3, 2023
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
March 21, 2023